Ophelia Maternal Care is here. And it's long overdue.
This Maternal Mental Health Awareness month, we're announcing something we've been working toward for a long time.
Every six minutes, an American dies of an opioid overdose. For pregnant patients managing opioid use disorder, the stakes are even higher and the access to care even worse. Many pregnant patients with OUD never get treated. Those who do often face stigma, uninformed providers, and care that drops them the moment they deliver. The evidence is clear and the treatment exists. The systems just weren't built for them.
Today, we're changing that.
We're formally launching Ophelia Maternal Care, a dedicated clinical program for pregnant and postpartum patients managing OUD, built on years of clinical experience, strong outcomes data, and a clear understanding of why this gap has persisted so long.
Pregnant patients with OUD face stigma from providers who don't know how to help, fragmented care that drops them at delivery, and dangerous misinformation telling them to stop their medication. We built Ophelia Maternal Health to address all of it: a specialized clinical team, protocols grounded in ACOG guidelines, and a fully virtual model that removes the access barriers keeping patients from care. We support postpartum psychiatric syndromes and help with advocacy, finding MOUD-friendly providers and connecting them with legal services in their state
The financial case is just as clear as the clinical one, and it operates on two levels. For all patients, not just pregnant people, Ophelia's outcomes data, drawn from a broad Medicaid population, shows a 70% reduction in total cost of care while in treatment, a 72% reduction in ED visits, and a 95% reduction in inpatient mental health costs. But the downstream savings matter just as much: when pregnant patients with OUD receive effective treatment, the costs that follow are dramatically different. Keeping patients in stable, evidence-based care during pregnancy is both the right clinical decision and what prevents those admissions from happening in the first place. For payors and MCOs managing this population, the return on covered MOUD treatment is significant and measurable.
Our program-specific outcomes speak for themselves. 100% of pregnant patients have screened positive for buprenorphine and 0% for opioids and 88% of patients in the program for 30 or more days have a BARC-10 score associated with long-term remission.
Ophelia Maternal Health is available now, fully virtual, covered by many Medicaid, Medicare, and commercial insurance across all Ophelia-licensed states. Referral pathways and program documentation are at ophelia.com/maternal-care.
If you, or a loved one, is pregnant or postpartum and looking for compassionate care, we're here to support. Text us at (215) 585 2144.
Sources
